Alnylam Pharma's total assets for Q2 2025 were $4.57B, an increase of 8.36% from the previous quarter. ALNY total liabilities were $4.32B for the fiscal quarter, a 5.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.